Ascelia Pharma Ab Is A Biotechnology Company Based In Malma Swedenfocused On Developing Treatments For Rare Cancer Conditionsfounded In 1999The Company Aims To Improve Outcomes For Patients With Complex Cancer Diagnoses Through Innovative Therapeutic And Diagnostic Solutionswith A Small Team Of Approximately 11Ae 13 Employeesascelia Pharma Operates In The Healthcare Sectorprioritizing Orphan Oncology Drug Development The Company Has Two Main Products In Its Pipelineorviglance Is A Non Gadolinium Contrast Agent Designed For Liver Mri Scansspecifically For Patients With Impaired Kidney Functionit Has Completed Phase Ii Trials And Is Currently In Phase Iii Developmentoncoral Is An Oral Formulation Of Irinotecanaimed At Enhancing Tolerability For Patients Undergoing Chemotherapy For Gastric Cancerand Is In Phase Ii Developmentascelia Pharma Targets Niche Markets With Limited Treatment Optionsemphasizing Regulatory Pathways For Orphan Drug Designation
